RGLS News Alert Regulus Therapeutics Inc (RGLS) 14.96 12/17/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Regulus Therapeutics Inc (RGLS) 14.96 $RGLS

Brinson Patrick's Christopher S. James: All Catalysts Are Not Created Equal
Life Sciences Report - Seeking Alpha - Fri Dec 05, 7:55AM CST
Why do some good-news milestones cause stocks to languish, or even fall? Neurosurgeon Christopher James, managing director and senior biotechnology analyst at Brinson Patrick Securities, performs due diligence on stocks, in part, by connecting his...
BCRX: 10.23 (+0.14), STEM: 0.85 (-0.06), RTRX: 11.12 (+0.56), RGLS: 14.96 (-0.49), SNY: 45.38 (+0.98), MNKD: 5.10 (-0.03)

Hepatocellular Carcinoma - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/8fjnjx/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 4SC - AbbVie - Acceleron Pharma - ACROVIS biostructures - Alfact Innovation - Alnylam - Amgen - AndroScienceration - ArQule - Arrowhead Researchration - Astex - AstraZeneca - Avidin Ltd - Bayer - Bio-Cancer Treatment - Blueprint Medicines - Boehringer Ingelheim - Boston Biomedical - Can-Fite BioPharma - CASI - CCRP Therapeutics - Celgeneration - Celsionration - China Medical System Holdings - Chroma Therapeutics - CrystalGenomics - CytRxration - Delcath Systems - Dicerna - Digna Biotech S.L. - Eisai. - Eli Lilly and Company - Endocyte - Exelixis - F. Hoffmann-La Roche - Gamida Cell - Geneluxration - Genoscience Pharma - GenSpera - GlaxoSmithKline - Green Cross Cellration - Immune Network - Immunicum AB - Immunomedics - Immunovative Therapies - Immuron - In Cell Art - Incuron LLC - Intezyne Inc - KAEL-GemVax. - KAHR medical - Kowa Company - La Jolla Pharmaceutical Company - Ligand - Lixte Biotechnology Holdings - MaxCyte - Merck KGaA - Millennium - MolMed S.p.A. - MultiCell Technologies - NeoStem - Nerviano Medical Sciences - Novartis - Nymox Pharmaceuticalration - Omerosration - Oncolys BioPharma - OncoTherapy Science - Ono Pharmaceutical. - Onxeo SA - Otsuka Holdings. - Panacea - Peregrine - Pfizer - PharmaEssentiaration - PhaseRx - Polaris - Priaxon - Progen - Provecs Medical - Provectus Biopharmaceuticals - Quantum - Raptor - Regulus Therapeutics - Rigontec - Santaris Pharma A/S - Sevion Therapeutics - Shanghai Sunway Biotech - Shenogen Pharma - Silence Therapeutics - SillaJen Co. - Simcere Pharmaceutical - Solasia Pharma K.K. - Synta - Taiwan Liposome Company - Tekmira - Therametrics holding - Therapure Biopharma - THERAVECTYS SA - Threshold - Toko Pharmaceutical Industries. - TRACON - Vaxon Biotech - Vertexrporated - Vicus Therapeutics LLC - Virttu Biologics For more information visit http://www.researchandmarkets.com/research/8f...tocellular
IMMU: 4.23 (+0.02), AMGN: 159.44 (-0.16), RGLS: 14.96 (-0.49), LLY: 69.26 (-0.41), GSK: 41.92 (+0.62), PVCT: 0.85 (-0.02), CANF: 3.35 (-0.17), DCTH: 1.34 (-0.01), NVS: 91.65 (+0.01), XLRN: 37.63 (-0.37)

Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference
PR Newswire - Wed Nov 26, 3:05PM CST
Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the 26th Annual Piper Jaffray Healthcare Conference at the New York Palace Hotel on Wednesday, December 3, 2014 at 2:00 p.m. EST. The presentation will be webcast at the time of the presentation and can be accessed on the Investor Relations page of Regulus' website at www.regulusrx.com. A replay of the webcast will be archived on Regulus' website following the presentation date.
RGLS: 14.96 (-0.49)

Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
The GeoTeam - Seeking Alpha - Tue Nov 25, 9:30AM CST
Earlier this month, investors witnessed another RNAi stock achieve incredible gains based on very early clinical trial data. The company, Regulus Therapeutics (NASDAQ: RGLS ), published its Hepatitis-C Phase I data from a pool of only 16 patients....
ROSG: 2.28 (-0.04), ISIS: 54.94 (-1.99), DRNA: 13.45 (+0.37), ALNY: 92.08 (-1.87), ARWR: 5.86 (+0.41), SRPT: 12.60 (-0.40), ALXN: 177.73 (-5.48), TKMR: 13.12 (-0.19), RGLS: 14.96 (-0.49)

European Ad Comm gives thumbs up to AbbVie's HCV combo
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 7:48AM CST

GILD: 100.46 (-2.70), ACHN: 12.92 (+0.20), CNAT: 7.82 (-0.02), MRK: 56.80 (-0.15), RGLS: 14.96 (-0.49), ABBV: 65.25 (-0.37), BMY: 57.69 (-0.86), ENTA: 41.14 (-1.97)

DexCom names Mark G. Foletta to board
M2 - Thu Nov 20, 5:38AM CST
Ambulatory glucose monitoring company DexCom (NasdaqGS XCM) revealed on Wednesday the addition of Mark G. Foletta as its independent board member.
DXCM: 53.26 (+0.41), RGLS: 14.96 (-0.49)

Regulus To See Further Declines
Richard Pearson - Seeking Alpha - Wed Nov 19, 9:30AM CST
On October 22nd, Regulus Therapeutics (NASDAQ: RGLS ) released its " proof of concept " data for its Hep C drug RG-101. The stock price quickly soared from its prior level of $6-7 to as high as $25 (intra day) as enthusiasm for the drug ran...
ISIS: 54.94 (-1.99), ALNY: 92.08 (-1.87), ACHN: 12.92 (+0.20), RGLS: 14.96 (-0.49)

Technical Updates on Biotech Stocks - ImmunoGen, Lexicon Pharma, ZIOPHARM Oncology, Arena Pharma, and Regulus Therapeutics
PR Newswire - Wed Nov 19, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regulus Therapeutics Inc. (NASDAQ: RGLS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 18, 2014, the NASDAQ Composite ended at 4,702.44, up 0.67%, the Dow Jones Industrial Average advanced 0.23%, to finish the day at 17,687.82, and the S&P 500 closed at 2,051.80, up 0.51%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 793.40, up 1.58%, with the index also advancing 12.08% in the last one month. Register for your complimentary reports on these five stocks at:
ZIOP: 4.08 (+0.09), LXRX: 0.86 (+0.01), IMGN: 9.83 (+0.43), RGLS: 14.96 (-0.49), ARNA: 3.78 (+0.06)

DexCom Announces Appointment of Mark G. Foletta as Board Member
Business Wire - Wed Nov 19, 7:30AM CST
DexCom, Inc. (NASDAQ XCM) today announced the appointment of Mark G. Foletta as an independent Board member of the company.
DXCM: 53.26 (+0.41), RGLS: 14.96 (-0.49)

Global miRNA Research and Diagnostics Markets Report 2014
M2 - Tue Nov 18, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjgcv3/mirna_research) has announced the addition of the "miRNA Research and Diagnostics Markets" report to their offering. This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that donot produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, alarge number of companies, both small biotechs and big pharmaceutical companiesare committed to miRNA diagnostics. As part of its coverage of this topic, this report includes the following: - Overview of miRNAs - Positive Factors for miRNA Diagnostic Technologies - Negative Factors - miRNAs and Neurological Disorders - miRNA and Metastatic Brain Lesions - Prostate Cancer Screening and miRNAs - miRNAs and Resistance to Anti-Cancer Drugs - Theoretical Limitations - Discussion of Patent Issues - Interviews with Industry Experts - Market Estimate As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail: - Agilent Technologies - AMSBIO - Applied Biosystems - DiamiR, LLC - Dicerna - Eisai Biomarkers and Personalized Medicine - Diagnostics - Genomic Health Inc. - Gensignia - GlaxoSmithKline Discovery and Molecular Toxicology - Groove Biopharma (formerly Mirina) - Hologic-Gen Probe Inc. - Illumina, Inc. - Isis Pharmaceuticals - Mello Biotechnology Inc. - Microlin Bio - MiRagen Therapeutics - MiRNA Therapeutics - Novartis - Pacific Edge Biotechnology - Prolias Technologies - Regulus Therapeutics - Rosetta Genomics - Santaris Pharma A/S - Sirnaomics, Inc. - Somagenics - Diagnostics: Small RNA Assays and Biomarker Validation - Tekmira Pharmaceuticals Corporation - Thermadiag - Thermo Fisher Scientific, Inc. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Current State of the Art 4. Companies Developing microRNA Diagnostic Technologies 5. Market Estimates and Forecasts 6. Interviews with Industry Experts: Biomarkers 7. The Future of miRNA-Based Diagnostics For more information visit http://www.researchandmarkets.com/research/fj...a_research
ISIS: 54.94 (-1.99), A: 38.47 (-0.21), TKMR: 13.12 (-0.19), ILMN: 175.18 (-3.13), RGLS: 14.96 (-0.49), GSK: 41.92 (+0.62), HOLX: 25.64 (+0.05), GHDX: 30.54 (+0.01), NVS: 91.65 (+0.01)

Strong On High Relative Volume: Regulus Therapeutics (RGLS)
at The Street - Tue Nov 18, 9:01AM CST
Trade-Ideas LLC identified Regulus Therapeutics (RGLS) as a strong on high relative volume candidate
RGLS: 14.96 (-0.49)

Critical Alerts For Zillow, Organovo, Regulus Therapeutics, JC Penney and FireEye Released By InvestorsObserver
PR Newswire - Mon Nov 17, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for Z, ONVO, RGLS, JCP and FEYE.
FEYE: 27.72 (-0.84), ONVO: 6.29 (-0.24), JCP: 6.32 (-0.09), RGLS: 14.96 (-0.49), Z: 111.83 (-6.37)

Regulus and Sanofi Present New Data Enhancing the Preclinical Profile of RG-012, an Anti-miR Targeting microRNA-21 for the Treatment of Renal Dysfunction in Alport Syndrome Patients, at ASN's Kidney Week 2014 Meeting
PR Newswire - Sat Nov 15, 5:00PM CST
Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that positive new preclinical data was presented on RG-012 for the treatment of renal dysfunction in Alport syndrome patients at the American Society of Nephrology's (ASN) Kidney Week 2014 meeting being held November 11-16, 2014 in Philadelphia, PA. Alport syndrome is a life-threatening, genetic kidney disease with no approved therapy, and currently, ACE (angiotensin-converting enzyme) inhibitors are emerging as standard of care to treat proteinuria, an indicator of chronic kidney disease (CKD) in these patients. Studies have shown that miR-21 plays a role in the progression of Alport syndrome and is up-regulated in mouse disease models, other renal fibrosis models and human CKD patients. These findings, and the new preclinical data presented at the ASN meeting, provide additional evidence that RG-012 may provide therapeutic benefit in the treatment of Alport syndrome.
RGLS: 14.96 (-0.49)

Regulus set for gap down on profit taking
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 8:22AM CST

RGLS: 14.96 (-0.49)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 8:10AM CST

MNK: 91.05 (-1.12), CYBR: 37.27 (-0.17), ZAZA: 1.28 (+0.04), FUEL: 15.03 (+0.06), ASTI: 1.05 (-0.06), RGLS: 14.96 (-0.49), SPWR: 23.71 (+0.45), DWA: 20.87 (+0.05), CIG: 4.58 (-0.11), AME: 48.73 (+0.07), JCP: 6.32 (-0.09), ICLD: 2.78 (-0.29), ALG: 47.80 (+0.09)

Regulus Therapeutics' (RGLS) CEO Kleanthis Xanthopoulos Presents at Credit Suisse 2014 Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 7:15PM CST

RGLS: 14.96 (-0.49)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:36PM CST

CYBR: 37.27 (-0.17), DKS: 48.69 (-1.43), SAND: 2.71 (-0.04), XONE: 15.64 (-0.25), FUEL: 15.03 (+0.06), RGLS: 14.96 (-0.49), ACM: 28.52 (-0.70), NTAP: 40.65 (-0.05), BZH: 17.02 (-0.36), DY: 30.80 (-0.16)

Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST

JNJ: 102.76 (-1.20), GILD: 100.46 (-2.70), ACHN: 12.92 (+0.20), CNAT: 7.82 (-0.02), MRK: 56.80 (-0.15), RGLS: 14.96 (-0.49), ABBV: 65.25 (-0.37), BMY: 57.69 (-0.86), ENTA: 41.14 (-1.97)

AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST

JNJ: 102.76 (-1.20), GILD: 100.46 (-2.70), ACHN: 12.92 (+0.20), CNAT: 7.82 (-0.02), MRK: 56.80 (-0.15), RGLS: 14.96 (-0.49), ABBV: 65.25 (-0.37), BMY: 57.69 (-0.86), ENTA: 41.14 (-1.97)

Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST

JNJ: 102.76 (-1.20), GILD: 100.46 (-2.70), ACHN: 12.92 (+0.20), CNAT: 7.82 (-0.02), MRK: 56.80 (-0.15), LGND: 51.54 (-0.70), RGLS: 14.96 (-0.49), ABBV: 65.25 (-0.37), BMY: 57.69 (-0.86), ENTA: 41.14 (-1.97)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 154

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 136

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 154

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 27

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 129

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 150

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading

Top 5 Most Recently Viewed Articles

Coca-Cola's Emerging Markets Strategy Fuels Long-Term Growth

Updated Category News Views 929

Coca-Cola's Position in Emerging Markets Coca-Cola Co (NYSE: KO) stands as a beacon of growth, with a visionary strategy that highlights both immediate and long-term opportunities. The company has successfully positioned itself in vital markets, particularly in North America and Latin America, which have proven central to its success. According to recent insights from...

Continue Reading
Voda IQ Appoints Armando Piccinini to Drive European Sales

Updated Category News Views 121

Voda IQ dropped some big news back in 2024 when they appointed Armando Piccinini as their European Sales Director. This guy’s got over twenty years under his belt in aquatic conservation, which they clearly hope will ramp up their sales strategy across Europe. But you gotta wonder—are the numbers behind this move really there? Can Experience Translate to Sales Growth?...

Continue Reading
Magnera Corporation to Shine at Upcoming Finance Conference

Updated Category News Views 163

Magnera Corporation's Conference Participation Announcement Magnera Corporation (NYSE: MAGN) has made an exciting announcement regarding its upcoming participation in a significant financial event. The company is set to be a part of the 2025 Bank of America Leveraged Finance Conference, aimed at fostering connections with top institutional investors. The event will take...

Continue Reading
Bullish Momentum Unveiled: Insights on Merck & Co Stocks

Updated Category News Views 180

Exciting Developments in Merck & Co Options Activity Notable investors are expressing strong optimism about Merck & Co. A recent analysis of options trading strategies reveals a wave of activity among traders aiming to capitalize on this potential. Options Trading Overview When reviewing the options history for Merck & Co (NYSE: MRK), we found a total of 33 trades that...

Continue Reading
Gilead Snags Arcellx: A High-Stakes Cancer Gamble Unfolds

Updated Category News Views 195

The Big Play for Cancer Innovation Gilead Sciences Inc. (NASDAQ:GILD) pulled the trigger on a pretty huge acquisition deal, landing Arcellx Inc. (NASDAQ:ACLX) this past Monday for a staggering $115 per share, which gets better with a potential extra $5 per share on a contingent value right. That rings in a hefty total of $7.8 billion—no pocket change, folks. What’s...

Continue Reading